Pegaptanib

Evidence Level: L5

Predicted Indications: 2

Pegaptanib

Pharmacist Assessment Report

Pegaptanib: From Macular Degeneration to Esophageal Varices with Bleeding

One-Sentence Summary

Pegaptanib was originally used to treat macular degeneration. The TxGNN model predicts it may be effective for esophageal varices with bleeding (and also esophageal varices without bleeding), but no clinical trials and no publications currently support this direction, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Macular degeneration
Predicted New Indication	Esophageal varices with bleeding (a second prediction, esophageal varices without bleeding, has the same score)
TxGNN Prediction Score	0.9919
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data
Number of Listed Products	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. From general knowledge, pegaptanib is a pegylated RNA aptamer that selectively binds VEGF-165, and it is used for macular degeneration, where VEGF-driven angiogenesis plays a central role.

A theoretical link to esophageal varices exists. VEGF-driven angiogenesis and the hyperdynamic splanchnic circulation contribute to portal hypertension and the formation of portosystemic collaterals, including varices. Blocking VEGF could in principle reduce this process.

However, the link is speculative. Pegaptanib is given by intravitreal injection with minimal systemic exposure, so it is unlikely to reach the portal or splanchnic circulation at relevant levels. The score for the bleeding and non-bleeding forms is identical (0.9919), which suggests it reflects a shared disease-node feature rather than evidence specific to each indication. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Systemic anti-VEGF agents can also impair hemostasis and wound healing and carry bleeding risk, which is a particular concern in active variceal hemorrhage. Standard care (non-selective beta-blockers, endoscopic band ligation) is well established, so any repurposing would need preclinical support first.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
142632	Macugen 0.3mg Infusion (Pfizer Ltd)	Bottle of 90 ml infusion (injectable)	Not stated in the available data

Safety Considerations

Please refer to the package insert for safety information.

No drug interaction records were found for this drug. Note that systemic anti-VEGF agents carry bleeding and impaired wound-healing risks, which would be a particular concern in active variceal hemorrhage.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the TxGNN model score (evidence level L5), with no clinical trials or literature. The intravitreal route gives minimal systemic exposure, and there is a bleeding-risk concern in variceal bleeding.

To proceed, the following is needed:

Preclinical evidence that VEGF inhibition affects portal hypertension or varices
A feasibility assessment of route and exposure, since the current product is intravitreal only
Detailed mechanism of action data (MOA)
Package insert warnings and contraindications from the India label
A bleeding-risk assessment specific to variceal hemorrhage
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.